Servei Assistencial

Presentació

Pathology service is a central service of theHospital which aims to give excellent care to the people also developing in teching and research in the area of health.

The Pathology Department examined tissue samples and body fluids in order to diagnose diseases of patients and attend the therapeutic decisions of of doctors of different care specialties.

pathologists and pathology technicians are specialists who also have the mission of prevention, early detection and diagnoss of cancer and other diseases .

The Pathology department perform clinical autopsies, not only to determinate the cause of death of ppatients,but also to give more information about the undercurrent diseases and the effects of the treatments used during the progression of the disease.

Althought our mission as a medical specialty remains the same, our scope has undergone major changes in recnt years due to technological advances in molecular biology .

`Pathologists diagnose not only trough the study of the microscopic and macroscopic tissue and cytological samples, but also generate information needed for decision making in the field of oncology. Analyze and interpret this information in the form of biomakers and molecular therapeutic targets that are useful towards establishing a personalized treatment and prognosis

Cartera de serveis

In Pathology Service of the Hospital Universitari de Girona Dr. Josep Trueta are diagnosed and processed following biological samples and apply in each case appropiate stains or techniques according to established protocols for the Service.

BIOPSIES

Surgical and preoperatives biopsies. Skin punctures and wedges skin. biopsies to determine the presence of nail fungs,Skin punctures and wedges ,nail biopsies to determine nail fungs, biopsies of oropharyngeal mucosa lesions and salivary glands to study of S. Sjögren, biopsies of cysts and maxillary tumors ,biopsies of nasal and paranasal passages, temporal artery biopsy and carotid artery artheerisclerotic plaques, arterial thromboembolism study, corneal and conjunctival biopsies, esterreotoxic biopsies of brain tumors and central nervous system demyelinating lesions, endoscopic biopsies of the digestive tract and respiratory, pleuralbiopsy,videotorascopie lungs biopsies of interstitial lung disease, pulmonary nodules and emphysema ,biopsies of lymph mediastinal by mediastinoscopy, biopsy needle thick cylinder tru-cuts of tumor lesions or pseudo , renal biopsies, biopsies of muscle and peripheral nerve,biopsy lymph node and bone marrow, liver biopsies, biopsies of tumor lesions or pseudotumoral sketal system,biopsies of bladder urine screening for prostata biopsies,legrats endometrial biopsy endometrial polyps by hysteroscopy,biopsies of uterine tuibes by ligation, biopsies vas deferens for male sterilization,cervical biopsies for study of injuries associated with HPV.

CYTOLOGIES

Sputum, nasal mucus, bronco-aspirated (BAS),washed alveolars bronchioles (BAL), exfoliative cytology pleural and ascetic fluid peritoneal, wasching bag Douglas, brushing cytology for billiar tract and bronchus, gynecological cytology of cervix and endometrial cytology ,cerebroespinal fluid cytology and fine needle aspirations (PAAF) of nodular lesions, tumoral and pseudotumoral.

AUTOPSIES

Clinical autopsies, no judicial. Autopsies clinical adult, pediatric, perinatals and fetus, including fetal autopsies legal interruption of pregancy due to congenital malformations, chromosomal , metabolic or maternal risk .

Processing technical legal autopsies of the Forensics Institute (Institut de Medicina Forense).

ROUTINE AND SPECIAL TECHNIQUES

Hematoxylin-Eosin, Papanicolaou, Periodic-Acid-Shiff (PAS), PAS-Alfa-Amilasa, PAS-Blau Alcià, Blue Alcian, Perls iron, Colloidal iron, Giemsa, Mucicarmín de Mayer, Masson trichrome,, Reticulin of Gomori, Silver methenamina of Jones, Elastic Verhoeff, Orceine, Ziehl-Neelsen, Fite, Gram, Grocott, Congo red, Congo red with Permanganat, Warthin-Starry, Osmium.

TECHNIQUES IMMUNOHISTOCHEMICAL (AUTOSTAINER)

Cytokeratin (CK)7,CK19, CK20, CKAE1/AE3, CK34ßE12, CK5/6, CKMNF-116, Desmin, Epithelial Antigen Ber EP4, Epithelial Membrane Antigen (EMA), Glial Fibrillarprotein Acidophilus(PGFA), Proteina S-100, Vimentin, Smooth muscle actin (SMA), smooth muscle myosin (SMM), Carcinoembriogenic antigen(CEA), Antigen associated epithelium (MOC-31), Antigen related breast cancer (GCDFP15), Prostate specific antigen (PSA), CA125, Antigen Hepatocitic specfic (Hepar-1), Thyroglobulin, Calcitonin, Collagen IV, Chromogranin, Synaptophysin, estrogen receptors , Progesteron receptors, HER-2 (HercepTest ™), p53, Ki-67, E-Cadherina, EGFR, HMB45, Melan-A, c-KIT, Pan-Melanom, PIN-cocktail, MLH1, MSH2, MSH6, PMS2, EBV-LMP1, Mieloperoxidasa, TdT, TTF-1, ALK1, Amiloide A, bcl-2, bcl-6, Calretinin, Cyclin D1, Cytomegalovirus, CD1a,CD3,CD4, CD5, CD8,CD10, CD15, CD20,CD21, CD23, CD30, CD31, CD34, CD43, CD45, CD45R0, CD56,CD61, CD68, CD79a, CD99, CD138, p16, Calponin, MUM-1, h-caldesmon, Miogenin, Mamoglobina, Carcinoma renal cells (RCC), Inhibin, N-Cadherin, D2-40, Placental alkaline phosphatase, α-1-Fetoprotein, Human chorionic gonadotropin , CDX-2, WT1, Kappa,Lambda,Pax5,ZAP-70,Glicoforin C,ß-Catenina,Herpes Virus Simplex 1,Napsin A,Factor XIII,HHV8.

DIRECT IMMUNOFLUORESCENCE TECHNIQUES

This methodology is used to determine the presence of immune complexes in diseases of the skin and Glomerulonephritis, marked by fluorescein antibody immunoglobulin heavy chains (IgA, IgG, IgM), light chains (Kappa, Lambda)and add fractions(C3).

Study bipsies should be sent fresh,isopent frozen , cut in cryostat and examined with a fluorescence microspcope.

MOLECULAR BIOLOGY TYECHNIQUES

- Determining the DNA of Human Papilloma Virus (VPH)

Protocol activities for the screening of cervical cancer of the Pla Director d’Oncologia del Servei Català de la Salut provides a test for determining high -risk ofHPV virus (VPH) with the following indications: inadequate screening history , ASC-US (women with uncertain diagnosis of lesions) and monitoring post- coniztion intrapitheal lesions.

In the Pathology Department implemented the ògica s’ha implementat la prova Hybrid Capture 2 test ( hc2 ) High-Risk HPV DNA Test ™ de Quigen, to serve as a reference center of Girona healthcare area.

-In situ hybridization technique with Fluorescein (FISH) in breast and gastric cancer, in suscebtibles patients recieving adjuvant Trastuzumab (Herceptin®).

The breast and stomach cancers overexpressing the protein HER-2 are associated with increased agressive biological tumor grow faster,a worse response to conventional chemotherapy and a increased risk of relapse after surgery and reduce survival. Detrmining the HER-2 protein expression is carried out in our service by using the technique mmunohistoquimia kit HercepTest ™. The tumor samples of patients who give a positive ( 3 + expression of membrane ) are candidates for treatment with Herceptin®, which is negative (0, 1 +) this theraqpy is not indicated for non response. In cases where you get a result inconclusive or indeterminate (2 +), is necessery to confirm or exclude the presence of a gene HER-2 using amplification technique FISH to determine whether or not the indication of treatment with Herceptin®.

-Study of breast cancer sentinel node System OSNA (One Step Nucleic Acid Amplification) (Sysmex®).

RNAm olecular analysis technique specific cytokeratin 19 tumor cells of breast cancer using RT-LAMP (reverse transcription-loop mediated isothermal amplification).

The study of the sentinel node breast cancer is usually done through the practice of intraoperative printing at the cutting surface ganglion and cytological study to determine the presence or abscence of tumor cells. If the result is positive the surgeon proceeds to make an axillary lymph node emtiyng. If the study is negative deferred node with serialized sections and immunohistochemical study for cytokeratins. In the study differed micrometastases are detected in 12-15% , of cases analyzed involved in the re-operation of the patient to practice emptying axillary lymph node.

Tje application of System OSNA in the estudy of the sentinel node is a quantitativ determination of mRNA of cytokeratin 19 all node using the same homogenisation,which allows you to set different results (isolated tumor cells, micrometastases i macrometastases),involving different therapeutic attitudes .

With the introduction of this technique a signifiant percentage of patients are spared a second surgery .

Equip

Head of service	Eugeni López-Bonet. Plantilla ICS.
Deputy doctors	Ferran Pérez Bueno
	M. Rosa Ortiz Duran
	Ester Díaz Gómez
	M. Àngels Quera González
	Raquel López Martos
	Mariana Turell Lorenzo
Biologists	Gloria Oliveras Serrat
Nursing staff
Head coach	Carmen Pérez Martínez
Technicians/Nurses	Dolors Garganta Roura
	Mercedes Cuadros Navarro
	Bernadeta Fabrega Canalias
	Olga Martinez Molina
	Adriana Espuña Massós
	Susana Serrano Sarra
	Carmen Pacheco Carrión
	Bibiana Cañigueral Julià
	Marta Serra Riba
Caretaker	Pedro Sotomayor Gabaldón
Adminstrative staff	Rita Agüero Ridao
	Josep Miquel Parés Valls
	Xavier Velasco Martinez
	Cristina Antunez Vitales

Docència

Teaching Pathology of the Hospital Universitari Dr. Josep Trueta de Girona is located on the -1 floor of the Hospital building. It has all the elements necessary for the acquisition of basic knowledge esssential for training new specialists:

Reception area and cut of samples from biopsies and cytology.
Technical area of preparation and drafting routine samples.
Autopsy room.
Medical offices equiped with microscope and one with photo camera.
Microscopes multi-heads
Immunohistochemistry and immunofluorescence
In situ fluorescent and hybridization techniques(FISH).
Electron Microscope.
Software since 1991.
File manually interesting cases for teaching.

Pathology service is divided into three main areas:

Biopsies,
Cytologies,
Autopsies.

All physicians except the Service manager are responsible for their autopsies. The area of biopsies is divided:

Digestive, otorinolaryngology and maxillofacial
Breast pathology , gynecological and urological
Skin
All the rest: limf node, hematopoietic, respiratory, CNS,soft tissues,bone etc.

Physicians on staff and place in property consists of:

Eugeni López i Bonet. Head of service. Responsible for biopsies breast pathology , gynecological and i urological. Tutor of Residents from 22 july 2008 to 1 january 2013.
Ferran Pérez i Bueno.Physician . Responsible for dermatopatology biopsies. breast Pathology , ginecological and urological .
Rosa Ortiz i Duran. Physician. Responsible for digestive, maxillofacial and otorinolaringology biopsies.

Interim doctors :

Mariana Turrell i Lorenzo. Citopathology and breast pathology, ginecology and urology.
Esther Díaz i Gómez. Pathology digestive, maxillofacial and otorinolaringology.
Raquel López i Martos. Pathology digestive, maxillofacial and otorinolaringology.
M. Àngels Quera González. Citopathology, pathology digestive, maxillofacial and otorinolaringology.Tutor of Residents from 1January 2013.

The teaching unit is credited with a medical per year.

TRAINING PROGRAMME FOR SPECIALITY

Recerca

COLLABORATION WITH THE TRANSLATIONAL RESEARCH UNIT OF THE DE INSTITUT CATALÀ D’ONCOLOGIA (ICO) DE GIRONA ( CATALAN INSTITUT OF ONCOLOGY)

In 2008 they began several lines of investigation the result of collaboration between the Translational Research Unit of the ICO Girona and Service Pathological of the Hospital Universitari de Girona Doctor Josep Trueta. These research projects co-directed by Dr. Javier A. Menéndez, head of Translational Research Unit of the ICO Girona and by Dr. Eugeni López Bonet of the Pathology service of the Hospital Universitari de Girona Doctor Josep Trueta. This This collaboration has fructified in the form of publications in prestigious international journals,lectures and presentations at international conferences and preparation of doctoral theses.

The lines of research begun with their productions are:

Sensors in the metabolic process of mitosis of tumor cells : molecular description, evaluation and clinical relevance :

Interaction between active state of kinase activated by monophosfat of adenine (P-AMPK) at M of the cell cycle of tumor cells.
AMPK: Evidence for an energy-sensing cytokinetic tumor suppressor.
Vazquez-Martin A, Oliveras-Ferraros C, Lopez-Bonet E, Menendez JA.
Cell Cycle. 2009 Nov 15;8(22):3679-83.
Mitotic kinase dynamics of the active form of AMPK (phospho-AMPKαThr172) in human cancer cells.
Vazquez-Martin A, López-Bonet E, Oliveras-Ferraros C, Pérez-Martínez MC, Bernadó L, Menendez JA.
Cell Cycle. 2009 Mar 1;8(5):788-91.

Descubrimiento y validación de Fosfo-AMPKa-Thr172 como marcador de mitosis en el carcinoma de mama: impact on histological grade.
Doctoral thesis by Eugeni López Bonet of Pathological service of the Hospital Universitari de Girona Doctor Josep Trueta, co-directedby Drs. J.A. Menéndez i Santiago Ramón y Cajal on 10 february 2012 and approved cum laude at the Universitat Autònoma de Barcelona.

Descubrimiento y validación de nuevos marcadores de mitosis en el carcinoma de mama: impact on histological grade.
Memòria presentada per Eugeni López Bonet del Servei d’Anatomia Patològica de l’Hospital Universitari de Girona Doctor Josep Trueta el 23 d’Octubre de 2010 a Madrid per a l’obtenció del títol de Master en Oncologia Molecular pel Centro Nacional de Investigaciones Oncológicas.

Cellular location of form self phosphorylated of mammalian target of rapamycin (P-mTOR) and kinase phosphorilated p70S6 (P-S6K1) tumor cell division.

Serine 2481-autophosphorylation of mammalian target of rapamycin (mTOR) couples with chromosome condensation and segregation during mitosis: confocal microscopy characterization and immunohistochemical validation of PP-mTOR(Ser2481) as a novel high-contrast mitosis marker in breast cancer core biopsies.
Lopez-Bonet E, Vazquez-Martin A, Pérez-Martínez MC, Oliveras-Ferraros C, Pérez-Bueno F, Bernadó L, Menendez JA.
Int J Oncol. 2010 Jan;36(1):107-15.

The serine 2481-autophosphorylated form of mammalian Target Of Rapamycin (mTOR) is localized to midzone and midbody in dividing cancer cells.
Vazquez-Martin A, Oliveras-Ferraros C, Bernadó L, López-Bonet E, Menendez JA.
Biochem Biophys Res Commun. 2009 Mar 13;380(3):638-43.

Monitoring autophosphorylation of mammalian target of rapamycin (mTOR) for histoprognostic grading of invasive breast cancer: impact on the reclassification of patients with grade 2 tumors using the Nottingham grading system.
Sauri-Nadal T, Del Barco S, Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Martin-Castillo B, Lopez-Bonet E, Menendez JA.
San Antonio Breast Cancer Symposium December 7, 2011,

Monitoring Phosphorylation of p70S6K1 Kinase (Thr421/Ser424), a Biological Marker for mTOR Activity, improves Nottingham Histoprognostic Grading of Invasive Breast Carcinomas.
Sauri-Nadal T, Del Barco S, Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Martin-Castillo B, Lopez-Bonet E, Menendez JA.
5th EORTC Annual Meeting on Molecular Markers in Cancer. Brussels, Belgium 27-29 October 2011.

Immunohistochemical analysis of the serine 2481-autophosphorylated form of mammalian target of rapamycin: a novel high-contrast mitosis marker in breast cancer core biopsies.
E. Lopez-Bonet, A. Vazquez-Martin, M.C. Perez-Martinez, C. Oliveras-Ferraros, F. Perez-Bueno, L. Bernadó, J.A. Menendez.
IMPAKT Breast Cancer Conference. Brussels, 7-9 May 2009.

Ser2481-autophosphorylated mTOR colocalizes with chromosomal passenger proteins during mammalian cytokinesis.
Vazquez-Martin A, Sauri-Nadal T, Menendez OJ, Oliveras-Ferraros C, Cufí S, Corominas-Faja B, López-Bonet E, Menendez JA.
Cell Cycle.2012 Nov15;11(22):4211-21.

Interactions and resistence mechanisms of antibodies against the Epidermal Growth Factor HER1 i HER2 receptors.

Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C, Corominas-Faja B, Cufí S, Vazquez-Martin A, Martin-Castillo B, Iglesias JM, López-Bonet E, Martin AG, Menendez JA.
Cell Cycle. 2012 Nov1;11(21):4020-32.

Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Torres-Garcia VZ, Sauri-Nadal T, Barco SD, Lopez-Bonet E, Brunet J, Martin-Castillo B, Menendez JA.
Biochem Biophys Res Commun. 2011 Apr 8;407(2):412-9.

Expression status of the autophagy-regulatory gene ATG6/BECN1 in ERBB2-positive breast carcinomas: bypassing ERBB2-induced oncogenic senescence to regulate the efficacy of ERBB2-targeted therapies.
Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Martin-Castillo B, Del Barco S, López-Bonet E, Menendez JA.
Genes Chromosomes Cancer. 2011 Apr;50(4):284-90.

Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castilló B, Pérez-Martínez MC, Cufí S, Del Barco S, Bernado L, Brunet J, López-Bonet E, Menendez JA.
Int J Oncol. 2010 Sep;37(3):669-78.

Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castillo B, Cufí S, Del Barco S, Lopez-Bonet E, Brunet J, Menendez JA.
Biochem Biophys Res Commun. 2010 Jun 18;397(1):27-33.

Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C, Vazquez-Martin A, López-Bonet E, Martín-Castillo B, Del Barco S, Brunet J, Menendez JA.
Int J Oncol. 2008 Dec;33(6):1165-76.

Genetic ablation or pharmacological inhibition of autophagy suppresses intrinsic resistance of breast cancer to HER2-targeted therapies.
Cufí S, Oliveras-Ferraros C, Vazquez-Martin A, Sauri-Nadal T, Del Barco S, Martin-Castillo B, Lopez-Bonet E, Menendez JA.
San Antonio Breast Cancer Symposium December 7, 2011.

Introduction of antidiabetic drug metformina in the treatment of breast carcinoma .

The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells.
Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B, Lopez-Bonet E, Menendez JA.
Oncol Rep. 2011 Jan;25(1):135-40.

Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology.
Martin-Castillo B, Dorca J, Vazquez-Martin A, Oliveras-Ferraros C, Lopez-Bonet E, Garcia M, Del Barco S, Menendez JA.
Ann Oncol. 2010 Jan;21(1):187-9.

Immunohistochemical study of primary neuroendocrine carcinoma of the breast.

Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine carcinomas of the breast.
Lopez-Bonet E, Pérez-Martínez MC, Martin-Castillo B, Alonso-Ruano M, Tuca F, Oliveras-Ferraros C, Cufí S, Vazquez-Martin A, Beltràn M, Bernadó L, Menendez JA.
Breast Cancer Res Treat. 2011 Feb;126(1):241-5.

Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling.
López-Bonet E, Alonso-Ruano M, Barraza G, Vazquez-Martin A, Bernadó L, Menendez JA.
Oncol Rep. 2008 Dec;20(6):1369-74.

Modeling tumor Stem cells

Discordant expression of molecular markers between primary and nodal metastases: a histopathological manifestation of the 'self (stem cell)-seeding' nature of breast cancer disease?
Lopez-Bonet E, Menendez JA.
Ann Oncol. 2010 Apr;21(4):901-2.

"Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency.
Vazquez-Martin A, Cufí S, López-Bonet E, Corominas-Faja B, Oliveras-Ferraros C, Martin-Castillo B, Menendez JA.
Sci Rep.2012;2:964.

Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
Martin-Castillo B, Oliveras-Ferraros C, Vazquez-Martrin A, Cufí S, Moreno JM, Corominas-Faja B, Urruticoechea A, Martín AG, López-Bonet E, Menendez JA.
Cell Cycle.2013 Jan 15;12(2):225-45.

The Warburg effect version 2.0: Metabolic reprogramming of cancer stem cells.
Menendez JA, Joven J, Cufí S, Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, Martin-Castillo B, López-Bonet E, Alarcón T, Vazquez-Martin A.
Cell Cycle. 2013 Apr 15;12(8):1166-79.

OTHER PUBLICATIONS WHO HAVE PARTICIPATED MEMBERS OF PATHOLOGY SERVICE (2010-2013)

Impacto de la obesidad en las caraterísticas anatomopatológicas de los tumores colorrectales. Estudio observacional.
Garcia-Oria MJ, Armengol M, Ortiz R, Codina-Cazador A.
Cir Esp. 2010;87(1):33-8.

Antimicrobial cyclic decapeptides with anticancer activity.
Feliu L, Oliveras G, Cirac AD, Besalú E, Rosés C, Colomer R, Bardaji E, Planas M, Puig T.
Peptides 2010Nov;31(11):2017-26.

Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+ breast cancer.
Oliveras G, Blancafort A, Urruticoechea A, Campuzano O, Gómez-Cabello D, Brugada R, López-Rodríguez ML, Colomer R, Puig T.
Ann NY Acad Sci. 2010Oct;1210:86-92

Epidemiologia del cáncer de cérvix in situ e invasor en la provincia de Girona 1990-2004: incidencia, mortalidad, supervivencia e historial de cribado.
Castro P, Moreno- Crespi J, Buxó M, Cervantes M, Pérez-Gómez B, Marcos-Gragera R.
Med Clin(Barc). 2011Feb;136(5):192-198.

Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994-2005.
Fuentes-Raspall R, Vilardell L, Pérez-Bueno F, Joly C, Garcia-Gil M, Garcia-Velasco A, Marcos-Gragera R.
J Neurooncol. 2011Jan;101(1):117-23.

Antibody microarray-based technology to rapidly define matrix metalloproteinase (MMP) signatures in patients undergoing resection for primary gastric carcinoma.
Puig-Costa M, Oliveras-Ferraros C, Flaquer S, Llopis-Puigmarti F, Pujol-Amado E, Martin-Castillo B, Vazquez-Martin A, Cufí S, Ortiz R, Roig J, Codina-Cazador A, Menéndez JA.
J Surg Oncol. 2011Jul;104(1):106-9.

Neuroendocrine tumors: A population-based study of incidence and survival in Girona province, 1994-2004.
Alsina M, Marcos-Gragera R, Capdevila J, Buxó M, Ortiz MR, Barretina P, Vilardell L, Brunet J, Beltran M, Izquierdo A.
Cancer Epidemiology 2011;35:49-54.

A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines.
Puig T, Aguilar H, Cufí S, Oliveras G, Turrado C, Ortega-Gutiérrez S, Benhamú B, López-Rodríguez ML, Urruticoechea A, Colomer R.
Breast Cancer Res. 2011Dec;13(6):R131.

Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinoma: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models.
Oliveras-Ferraros C, Vazquez-Martin A, Queralt B, Adrados M, Ortiz R, Cufí S, Hernández-Yagüe X, Guardeño R, Báez L, Martin-Castillo B, Pérez-Martínez MC, López-Bonet E, De Llorens R, Bernadó L, Brunet J, Menendez JA.
Int J Oncol. 2011Dec;39(6):1455-79.

Perfomance of the digene LQ, RH and PS HPVs genotyping systems on clinical samples and comparison with HC2 and PCR-based linear array.
Godínez JM, Tous S, Baixeras N, Moreno-Crespi J, Alejo M, Lejeune M, Bravo IG, Bosch FX, De Sanjose S.
Infec Agent Cancer 2011;6:23.

Prediccion of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of unetermined significance (ASC-US) in Catalonia, Spain.
Ibáñez R, Moreno-Crespi J, Sardà M, Autonell J, Fibla M, Gutiérrez C, Lloveras B, Alejo M, Català I, Alameda F, Casas M, Bosch FX, De Sanjosé S.
BMC Infec Dis. 2012;12:25.

Comparison of molecular analysis and histopathology for axillary lymph node staging in primary breast cancer: results of the B-CLOSER-I study.
Bernet L, Rojo F, Hardisson D, Córdoba A, Panadés MJ, Velasco A, López-Bonet E, Cano R, Polo L.
Diagn Mol Pathol. 2012Jun;21(2):69-76.

New synthetic inhibitors of fatty acid synthase with anticancer activity.
Turrado C, Puig T, Garcia-Cárceles J,Artola M, Benhamú B, Ortega-Gutiérrez S, Relat J, Oliveras G, Blancafort A, Haro D, Marrero PF, Colomer R, López-Rodríguez ML.
J Med Chem. 2012Jun;55(11):5013-23.

Different fatty acid metabolism effects of (-)-Epigallocatechin-3-Gallate and C75 in adenocarcinoma lung cancer.
Relat j, Blancafort A, Oliveras G, Cufí S, Haro D, Marrero PF, Puig T.
BMC Cancer 2012Jul;12(1):280.

Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
Carrion-Salip D, Panosa C, Menendez JA, Puig T, Oliveras G, Pandiella A, De Llorens R, Massaguer A.
Int J Oncol.2012Sep;41(3):1128-38.

Quiz page August 2012: a man with nephrotic syndrome and a mediastinal mass.
Faur D, Martín N, Archuleta JM, Torguet P.
Am J Kidney Dis. 2012 Aug;60(2):A25-7.

Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agents.
Menendez JA, Joven J, Aragonès G, Barrajón-Catalán E, Beltán-Debón R, Borrás-Linares I, Camps J, Corominas-Faja B, Cufí S, Fernández-Arroyo S, Garcia-Heredia A, Hernández-Aguilera A, Herranz-López M, Jiménez-Sánchez C, López-Bonet E, Lozano-Sánchez J, Luciano-Mateo F, Martin-Castillo B, Martin-Paradero V, Pérez-Sánchez A, Oliveras-Ferraros C, Riera-Borrull M, Rodríguez-Gallego E, Quirantes-Piné R, Rull A, Tomás-Menor L, Vazquez-Martin A, Alonso-Villaverde C, Micol V, Segura-Carretero A.
Cell Cycle. 2013 Feb 15;12(4):555-78.

A diagnosic approach to the mediastinal masses.
Juanpere S, Cañete N, Ortuño P, Martínez G, Bernadó L
Insights Imaging. 2013Feb;4(19):29-52.

Synchronous solid neuroendocrine breast carcinoma and abdominal lymphoma: A case report and review of the literature.
Alonso-Ruano M, López-Bonet E, Huerta-Anaya MV, Vila-Camps E, Bernadó L, Tuca-Rodríguez F, Suarez-Pumariega P, Menendez JA.
Oncol Lett. 2013Feb;5(2):459-462.

Albuminin-binding MR blood pool contrast agent improves diagnosic performance in human brain tumour: comparison of two contrast agents for glioblastoma.
Puig J, Blasco G, Essig M, Daunis-I-Estadella J, Laguillo G, Quiles AM, Remollo S, Bergmann K, Joly C, Bernadó L, Sánchez-González J, Pedraza S.
Eur Radiol. 2013Apr;23(4):1093-101.

α2,3-sialyltransferase ST3Gal IV promotes migration and metastasis in pancreatic adenocarcinoma cells and tends to be highly expressed in pancreatic adenocarcinoma tissues.
Pérez-Garay M, Arteta B, Llop E, Cobler L, Pagès L, Ortiz R, Ferri MJ, de Bolos C, Figueras J, de Llorens R, Vidal-Vanaclocha F, Peracaula R.
Int J Biochem Cell Biol. 2013May28. doi:pii: S1357-2725(13)00152-O. 10.1016/j.biocel.2013.05.015.(Epub ahead of print).

Àmbit:

Hospital

GTranslate

ICS Girona

Pathology

Servei Assistencial

TRAINING PROGRAMME FOR SPECIALITY

Àmbit:

GTranslate

Search form

Servei Assistencial

TRAINING PROGRAMME FOR SPECIALITY

Àmbit: